Table 3.
Therapeutic effects of porphyrins in central nervous system (CNS)-related disorders/injuries
| CNS-related disorders/injuries | Porphyrins | Animal/cells | References |
|---|---|---|---|
| Stroke | MnTE-2-PyP5+ MnTDE-2-ImP5+ MnTnHex-2-PyP5+ |
rodents | 85, 106, 159, 160 |
|
| |||
| Spinal cord injury | MnTE-2-PyP5+ MnTDE-2-ImP5+ FeTSPP3– WW-85 MnTBAP3– |
mice | 6, 165–170 |
|
| |||
| Subarachnoid hemorrhage | MnTnHex-2-PyP5+ | mice | 85 |
|
| |||
| Cerebral palsy | MnTnHex-2-PyP5+ | rabbit dams | 161 |
|
| |||
| Amyotrophic lateral sclerosis | MnTnHex-2-PyP5+ MnTDE-2-ImP5+, FeTBAP3- |
mice | 87, 178, 179, 197 |
|
| |||
| Parkinson's disease | MnTBAP3– | cells | 180 |
| AEOL11207 | mice | ||
|
| |||
| Alzheimer's disease | MnTE-2-PyP5+ | cells | 182 |
|
| |||
| Epilepsy | AEOL 11207 | mice | 181 |
|
| |||
| Oxygen and glucose deprivation | MnTE-2-PyP5+ MnTDE-2-ImP5+ MnTnHex-2-PyP5+ MnTnOct-2-PyP5+ |
cells | 183 |
|
| |||
| Staurosporine-induced neurotoxicity | MnTM-4-PyP5+,
H2TM-4-PyP4+,
ZnTM-4-PyP4+, MnTM-2-PyP5+, MnTE-2-PyP5+, MnTBAP3–, ZnTBAP4– |
cells | 198 |
|
| |||
| Neuropathic pain | MnTCHP+ (SR16), MnTE-2-PyP5+ | mice | 44, 211 |
|
| |||
| Chronic morphine tolerance | MnTnHex-2-PyP5+ MnTE-2-PyP5+ |
mice | 172 |
Listed are the diseases where beneficial effects were observed, the Mn porphyrin name, the animal tested and the related references.